A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women

AIDS

Volumn 16, Issue 16, 2002, Pages 2175-2182

  Howard, Andrea A ^a   Arnsten, Julia H ^a   Lo, Yungtai ^a   Vlahov, David ^b,c   Rich, Josiah D ^d   Schuman, Paula ^e   Stone, Valerie E ^d   Smith, Dawn K ^f   Schoenbaum, Ellie E ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c NEW YORK ACADEMY OF MEDICINE   (United States)

^d BROWN UNIVERSITY   (United States)

^e WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Adherence; Antiretroviral therapy; Compliance; Drug users; Electronic monitoring; Viral load; Women

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG USE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DRUG COMBINATIONS; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; MULTIVARIATE ANALYSIS; PATIENT COMPLIANCE; PROSPECTIVE STUDIES; SUBSTANCE-RELATED DISORDERS; VIRAL LOAD;

EID: 0037045043     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200211080-00010     Document Type: Article

References (32)

1. Collier AC, Coombs RW, Schoenfeld DA, Bassett RL, Timpone J, Baruch A, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med 1996, 334:1011-1017.
2. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997, 337:734-739.
3. Autran B, Carcelain G, Li TS, Blanc C, Mafher D, Tubiana R, et al. Positive effect of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997, 277:112-116.
4. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuher J, Satten GA, et al. and the HIV Outpatient Study Investigators. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998, 338:853-860.
5. Shapiro MF, Morton SC, McCaffrey DF, Andersen RM, Berk ML, Bins EG, et al. Variations in the care of HIV-infected adults in the United States: Results from the HIV Cost and Services Utilization Study. JAMA 1999, 281:2305-2315.
6. Celentano DD, Vlahov D, Cohn S, Shadle VM, Obasanjo O, Moore RD. Self-reported antiretroviral therapy in injection drug users. JAMA 1998, 280:544-546.
7. Bassetti S, Battegay M, Furrer H, Rickenbach M, Flepp M, Kaiser L, et al. Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? J Acquir Immune Defic Syndr 1999, 21:114-119.
8. Wainberg MA, Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA 1998, 279:1977-1983.
9. Singh N, Squier C, Sivek C, Wagener M, Hong Nguyen M, Yu VL. Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: Prospective assessment with implications for enhancing compliance. AIDS Care 1996, 8:261-269.
10. Wenger N, Gifford A, Liu H, Chesney M, Golin C, Crystal S, et al. Patient characteristics and attitudes associated with antiretroviral adherence. Sixth Conference on Retroviruses and Opportunistic Infections. Chicago, February 1999 [abstract 98].
11. Haubrich RH, Little S, Currier JS, Forthal D, Kemper C. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. AIDS 1999, 13:1099-1107.
12. Montessori V, Heath KV, Yip B, Hogg RS, O'Shaughnessy MV, Montaner JSG. Predictors of adherence with triple combination therapy. Seventh Conference on Retroviruses and Opportunistic Infections. San Francisco, 2000 [abstract 72].
13. Kalichman SC, Ramachandran B, Catz S. Adherence to combination antiretroviral therapies in HIV patients of low health literacy. J Gen Intern Med 1999, 14:267-273.
14. Mostashari F, Riley E, Selwyn PA, Altice FL. Acceptance and adherence with antiretroviral therapy among HIV-infected women in a correctional facility. J Acquir Immune Def Syndr Hum Retrovirol 1998, 18:341-348.
15. Singh N, Berman SM, Swindells S, Justice JC, Mohr JA, Squier, C et al. Adherence of human immunodeficiency virus-infected patients to antiretroviral therapy. Clin Infect Dis 1999, 29:824-830.
16. Paterson DL, Swindells S, Mohr J, Brester M, Squier C, Wagener MM, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000, 133:21-30.
17. Bangsberg DR, Hecht FM, Charlebois ED, Zolopa AR, Holodniy M, Sheiner L, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 2000, 14:357-366.
18. Gordillo V, del Amo J, Soriano V, Gonzalez-Lahoz H. Socio-demographic and psychological variables influencing adherence to antiretroviral therapy. AIDS 1999, 13:1763-1769.
19. Holzemer WL, Corless IB, Nokes KM, Turner JG, Brown MA, Powell-Cope GM, et al. Predictors of self-reported adherence in persons living with HIV disease. AIDS Patient Care and STDs 1999, 13:185-197.
20. Gao X, Nau DP, Rosenbluth SA, Scott V, Woodward C. The relationship of disease severity, health beliefs and medication adherence among HIV patients. AIDS Care 2000, 12:387-398.
21. Arnsten JH, Demas PA, Grant RW, Gourevitch MN, Farzadegan H, Howard AA, et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med 2002, 17:377-381.
22. McNabb J, Ross JW, Abriola K, Turley C, Nightingale CH, Nicolau DP. Adherence to highly active antiretroviral therapy predicts virologic outcome at an inner-city human immunodeficiency virus clinic. Clin Infect Dis 2001, 33:700-705.
23. Liu H, Golin CE, Miller LG, Hays RD, Beck CK, Sanandaji S, et al. A comparison of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med 2001, 134:968-977.
24. Carrieri P, Cailleton V, Le Moing V, Spire B, Dellamonica P, Bouvet E, et al. The dynamic of adherence to highly active antiretroviral therapy: Results from the French National APROCO cohort. J Acquir Immune Def Syndr 2001, 22:232-239.
25. Mannheimer S, Friedland G, Matts J, Child C, Chesney M, for the Terry Beirn Community Programs for Clinical Research on AIDS. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis 2002, 34:1115-1121.
26. Arnsten JH, Demas PA, Farzadegan H, Grant RW, Gourevitch MN, Chang CJ, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: Comparison of self-report and electronic monitoring. Clin Infect Dis 2001, 33:1417-1423.
27. Feinstein A. On white-coat effects and the electronic monitoring of compliance. Arch Intern Med 1990, 150:1377-1388.
28. Stone VE. Strategies for optimizing adherence to highly active antiretroviral therapy: Lessons from research and clinical practice. Clin Infect Dis 2001, 15:865-872.
29. Smith DK, Warren DL, Vlahov D, Schuman P, Stein MD, Greenberg BL, et al. Design and baseline participant characteristics of the Human immunodeficiency virus Epidemiology Research (HER) Study: A prospective cohort study of human immunodeficiency virus infection in US women. Am J Epidemiol 1997, 146:459-469.
30. Golin C, Liu H, Hays R, Ickovics J, Beck K, Miller L, et al. Self-reported adherence to protease inhibitors substantially over-estimates an objective measure. Sixth Conference on Retroviruses and Opportunistic Infections. Chicago, 1999 [abstract 95].
31. Melbourne KM, Geletko SM, Brown SL, Willey-Lessne C, Chase S, Fisher A. Medication adherence in patients with HIV infection: A comparison of two measurement methods. AIDS Reader 1999, 9:329-338.
32. Centers for Disease Control and Prevention. HIV/AIDS among U.S. women: Minority and young women at continuing risk. CDC Fact Sheet 1999, 1-2.